Overall, we show a marked difference between ALDH activity of HSC and LSC within the AML BM indicating the importance of ALDH activity as a functional stem cell biomarker and its potential usefulness in identification and purification of HSC and LSC, with the aim of treatment decision making, relapse prediction and development of LSC-specific therapies. The gene discussed is LDHA; the disease is acute myeloid leukemia.